# HCW Biologics Inc. (HCWB) — capital_raise/atm_program [pending]
Source: SEC API (secapi.ai) · situation sit_f2da43b798b3226fcb06 · retrieved 2026-08-11T15:54:04.942Z

## Overview
HCW Biologics Inc. is a pharmaceutical company developing clinical-stage therapeutics; the filing indicates the company intends to use net proceeds for working capital and general corporate purposes, including continuing clinical development activities.

HCW Biologics Inc. entered into a Securities Purchase Agreement on July 29, 2026 with accredited investors to issue and sell 618,682 units at prices of $2.585 per unit (for common stock) or $2.5849 per unit (for pre-funded warrants). Each unit includes either one share of common stock or one pre-funded warrant, plus the right to receive one common stock purchase warrant upon stockholder approval. The offering comprises 218,682 shares of common stock and 400,000 pre-funded warrants, generating approximately $1.6 million in gross proceeds before offering expenses. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants will have an exercise price of $2.585 per share, be exercisable immediately upon issuance (following stockholder approval), and expire 5.5 years from issuance. Company insiders including CEO Hing C. Wong, Board Chairman Scott Garrett, and SVP Lee Flowers participated on the same terms as other investors.

## Terms
- Counterparty: Accredited investors · Deal value: $1.6M · Consideration: cash · Price/share: $2.585

## Key dates
- Announced 2026-07-29

## Timeline
- 2026-07-29 · 8-K (0001493152-26-035233): 8-K - HCW Biologics Inc. — *HCW Biologics Inc. is a pharmaceutical company developing clinical-stage therapeutics; the filing indicates the company intends to use net proceeds for working capital and general corporate purposes, including continuing clinical development activities.* HCW Biologics Inc. entered into a Securities Purchase Agreement on July 29, 2026 with accredited investors to issue and sell 618,682 units at prices of $2.585 per unit (for common stock) or $2.5849 per unit (for pre-funded warrants). Each unit includes either one share of common stock or one pre-funded warrant, plus the right to receive one common stock purchase warrant upon stockholder approval. The offering comprises 218,682 shares of common stock and 400,000 pre-funded warrants, generating approximately $1.6 million in gross proceeds before offering expenses. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants will have an exercise price of $2.585 per share, be exercisable immediately upon issuance (following stockholder approval), and expire 5.5 years from issuance. Company insiders including CEO Hing C. Wong, Board Chairman Scott Garrett, and SVP Lee Flowers participated on the same terms as other investors.
  https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-035233.txt

## Citations
- 0001493152-26-035233 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226035233